Several salvage regimens exist for platinum refractory cases including Topoisomerase I inhibitors (e.g., Topotecan), Topoisomerase II inhibitors (Etoposide or Doxorubicin), microtubule inhibitors (Vinorelbine), alkylating reagents (Altretamine, Ifosfamide), anti-metabolites (Gemcitabine), estrogen receptor (ER) inhibitors (Tamoxifen, in ER-positive tumours) and epidermal growth factor receptor 2 (HER2) inhibitors (Herceptin, in HER2-positive tumours). Here, ERBB2 is linked to neoplasm.